PMID- 28336215
OWN - NLM
STAT- MEDLINE
DCOM- 20180309
LR  - 20221207
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
VI  - 31
IP  - 5
DP  - 2017 May
TI  - Association of increased levels of MCP-1 and cathepsin-D in young onset type 2 
      diabetes patients (T2DM-Y) with severity of diabetic retinopathy.
PG  - 804-809
LID - S1056-8727(16)30839-X [pii]
LID - 10.1016/j.jdiacomp.2017.02.017 [doi]
AB  - AIM: Young onset type 2 diabetes patients (T2DM-Y) have been shown to possess an 
      increased risk of developing microvascular complications particularly diabetic 
      retinopathy. However, the molecular mechanisms are not clearly understood. In 
      this study, we investigated the serum levels of monocyte chemotactic protein 1 
      (MCP-1) and cathepsin-D in patients with T2DM-Y without and with diabetic 
      retinopathy. METHODS: In this case-control study, participants comprised 
      individuals with normal glucose tolerance (NGT=40), patients with type 2 diabetes 
      mellitus (T2DM=35), non-proliferative diabetic retinopathy (NPDR=35) and 
      proliferative diabetic retinopathy (PDR=35). Clinical characterization of the 
      study subjects was done by standard procedures and MCP-1 and cathepsin-D were 
      measured by ELISA. RESULTS: Compared to control individuals, patients with 
      T2DM-Y, NPDR and PDR exhibited significantly (p<0.001) higher levels of MCP-1. 
      Cathepsin-D levels were also significantly (p<0.001) higher in patients with 
      T2DM-Y without and with diabetic retinopathy. Correlation analysis revealed a 
      positive association (p<0.001) between MCP-1 and cathepsin-D levels. There was 
      also a significant negative correlation of MCP1/cathepsin-D with C-peptide 
      levels. The association of increased levels of MCP-1/cathepsin-D in patients with 
      DR persisted even after adjusting for all the confounding factors. CONCLUSION: As 
      both MCP-1 and cathepsin-D are molecular signatures of cellular senescence, we 
      suggest that these biomarkers might be useful to predict the development of 
      retinopathy in T2DM-Y patients.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Reddy, Sruthi
AU  - Reddy S
AD  - Department of Cell and Molecular Biology and Dr. Rema Mohan High-Throughput 
      Screening (HTS) Lab, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes 
      Specialities Centre, Gopalapuram, Chennai 600086, India.
FAU - Amutha, Anandakumar
AU  - Amutha A
AD  - Department of Cell and Molecular Biology and Dr. Rema Mohan High-Throughput 
      Screening (HTS) Lab, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes 
      Specialities Centre, Gopalapuram, Chennai 600086, India.
FAU - Rajalakshmi, Ramachandran
AU  - Rajalakshmi R
AD  - Department of Cell and Molecular Biology and Dr. Rema Mohan High-Throughput 
      Screening (HTS) Lab, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes 
      Specialities Centre, Gopalapuram, Chennai 600086, India.
FAU - Bhaskaran, Regin
AU  - Bhaskaran R
AD  - Department of Cell and Molecular Biology and Dr. Rema Mohan High-Throughput 
      Screening (HTS) Lab, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes 
      Specialities Centre, Gopalapuram, Chennai 600086, India.
FAU - Monickaraj, Finny
AU  - Monickaraj F
AD  - Department of Surgery and Department of Cell Biology and Physiology, University 
      of New Mexico School of Medicine, Albuquerque, NM, USA.
FAU - Rangasamy, Sampathkumar
AU  - Rangasamy S
AD  - Neurogenomics Division, Translational Genomics Research Institute, (TGen), 
      Phoenix, AZ, USA.
FAU - Anjana, Ranjit Mohan
AU  - Anjana RM
AD  - Department of Cell and Molecular Biology and Dr. Rema Mohan High-Throughput 
      Screening (HTS) Lab, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes 
      Specialities Centre, Gopalapuram, Chennai 600086, India.
FAU - Abhijit, Shiny
AU  - Abhijit S
AD  - Department of Cell and Molecular Biology and Dr. Rema Mohan High-Throughput 
      Screening (HTS) Lab, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes 
      Specialities Centre, Gopalapuram, Chennai 600086, India.
FAU - Gokulakrishnan, Kuppan
AU  - Gokulakrishnan K
AD  - Department of Cell and Molecular Biology and Dr. Rema Mohan High-Throughput 
      Screening (HTS) Lab, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes 
      Specialities Centre, Gopalapuram, Chennai 600086, India.
FAU - Das, Arup
AU  - Das A
AD  - Department of Surgery and Department of Cell Biology and Physiology, University 
      of New Mexico School of Medicine, Albuquerque, NM, USA.
FAU - Mohan, Viswanathan
AU  - Mohan V
AD  - Department of Cell and Molecular Biology and Dr. Rema Mohan High-Throughput 
      Screening (HTS) Lab, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes 
      Specialities Centre, Gopalapuram, Chennai 600086, India.
FAU - Balasubramanyam, Muthuswamy
AU  - Balasubramanyam M
AD  - Department of Cell and Molecular Biology and Dr. Rema Mohan High-Throughput 
      Screening (HTS) Lab, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes 
      Specialities Centre, Gopalapuram, Chennai 600086, India.. Electronic address: 
      balusignal@gmail.com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20170310
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
RN  - 0 (Biomarkers)
RN  - 0 (C-Peptide)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (hemoglobin A1c protein, human)
RN  - EC 3.4.23.5 (CTSD protein, human)
RN  - EC 3.4.23.5 (Cathepsin D)
RN  - Maturity-Onset Diabetes of the Young, Type 2
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - C-Peptide/blood
MH  - Case-Control Studies
MH  - Cathepsin D/*blood
MH  - Chemokine CCL2/*blood
MH  - Confounding Factors, Epidemiologic
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diabetic Retinopathy/*blood/epidemiology/physiopathology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - India
MH  - Male
MH  - Reproducibility of Results
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - *Up-Regulation
MH  - Young Adult
OTO - NOTNLM
OT  - Biomarkers
OT  - Cathepsin-D
OT  - Diabetic Retinopathy
OT  - MCP-1
OT  - T2DM-Y
EDAT- 2017/03/25 06:00
MHDA- 2018/03/10 06:00
CRDT- 2017/03/25 06:00
PHST- 2016/11/12 00:00 [received]
PHST- 2017/01/25 00:00 [revised]
PHST- 2017/02/13 00:00 [accepted]
PHST- 2017/03/25 06:00 [pubmed]
PHST- 2018/03/10 06:00 [medline]
PHST- 2017/03/25 06:00 [entrez]
AID - S1056-8727(16)30839-X [pii]
AID - 10.1016/j.jdiacomp.2017.02.017 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2017 May;31(5):804-809. doi: 
      10.1016/j.jdiacomp.2017.02.017. Epub 2017 Mar 10.